Back to the Top
I want to make SR tablets and do clinical study. But metabolite of drug is also having the therapeutic action. Half life to drug is 4-5 hrs and that of metabolite is 10 hrs.
What are things to be considered when developing such kind of dosage forms? In clinical study it will show 2 AUC for active and its metabolite.so how its compared with invitro data?
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Clinical Study of API and its active metabolite" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)